Another monoclonal antibody for Alzheimer’s to get FDA review
Some scientists aren’t hopeful that lecanemab, following in the footsteps of its unsuccessful predecessor, will shake things up
Some scientists aren’t hopeful that lecanemab, following in the footsteps of its unsuccessful predecessor, will shake things up